J&J's Stelara shows promise against lupus in study

(Reuters) - Johnson & Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Saturday.